newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

  • Bezucalastinib plus sunitinib achieved a 16.5-month median progression-free survival (mPFS) versus 9.2 months for sunitinib monotherapy (HR=0.50, p<0.0001) in Phase 3 PEAK trial for imatinib-resistant GIST.
  • The combination demonstrated a 46% objective response rate (ORR) compared to 26% for sunitinib monotherapy (p<0.0001).
  • The safety profile was well-tolerated with no unique risks observed relative to sunitinib monotherapy.
  • Cogent Biosciences plans to submit a new drug application (NDA) for bezucalastinib in GIST in the first half of 2026.
  • Full PEAK trial results are scheduled to be presented at a scientific conference in the first half of 2026.
  • An Expanded Access Program is currently available for GIST patients requiring immediate access to the treatment.
  • Estimated mean duration of treatment for the bezucalastinib combination is projected to exceed 19 months.
  • Top-line results from the registration-directed APEX trial in Advanced Systemic Mastocytosis are expected in December 2025.
  • Cogent intends to submit an NDA for bezucalastinib in NonAdvanced Systemic Mastocytosis patients by the end of 2025.
  • Cogent will host an investor webcast on November 10, 2025, at 8:00 a.m. ET to discuss the PEAK trial data.